In this section, we will provide a brief summary and a link to the published abstract of newly published papers selected from the worldwide literature as being of particular interest to the SelfCare community.
Consumer self-selection, safety, and compliance with a novel over-the-counter ibuprofen 600-mg immediate-release and extended-release tablet
By: Paluch E, Jayawardena S, Wilson B, Farnsworth S.
Journal of the American Pharmacists Association 2016;56:397-404.
Summary: This study evaluated whether consumers can correctly select and use a new long-acting ibuprofen 600-mg immediate-release and extended-release (IR/ER) product. On the primary endpoint, 69.1% overall made a correct selection, 63.5% correctly selected ibuprofen IR/ER for pain, and 5.6% correctly avoided selecting ibuprofen IR/ER for shorter-lasting pain. Overall, 82.7% chose correctly (when subjects who picked ibuprofen IR for pain >=6 hours were excluded). Only 5 participants were excessive users. No excessive user experienced an adverse event.